The Valuation of JUUL Continues to Fall

0
1547

Currently, the U.S. Food and Drug Administration is conducting a scientific review of JUUL’s Premarket Tobacco Application (PMTA). Billy Gifford, CEO of Altria Group, told analysts that he expects the e-vapor category to continue to undergo a transition period over the next few years as the FDA reviews and makes determinations on the various PMTAs it has received.

For all the latest news from Altria Group, visit altria.com.